NovoCure Reports Q4/FY25 Results, Guides Towards 2026 Profitability Amidst CMO Resignation
Summary
NovoCure reported Q4 and full-year 2025 financial results, showing 8% revenue growth, and provided 2026 guidance projecting a significant improvement in Adjusted EBITDA towards profitability, alongside operational updates and the resignation of its Chief Medical Officer.
Key Events
-
Reports Q4 and Full-Year 2025 Financial Results
NovoCure reported full-year 2025 net revenues of $655.4 million, an 8% increase year-over-year, and Q4 net revenues of $174.4 million, also up 8% year-over-year. The company posted a net loss of $24.5 million for Q4 and an Adjusted EBITDA of $(16.4) million.
-
Provides 2026 Financial Guidance
The company issued 2026 guidance projecting total net revenues between $675 million and $705 million, and Adjusted EBITDA between $(20) million and $0 million, indicating a significant move towards profitability from $(34.3) million in 2025.
-
Chief Medical Officer Resigns
Dr. Nicolas Leupin, Chief Medical Officer, resigned effective February 25, 2026. Chief Innovation Officer Uri Weinberg will lead the organization previously reporting to Dr. Leupin.
-
Operational Growth and Reporting Changes
As of December 31, 2025, there were 4,620 active patients on TTFields therapy globally. The company announced it will stop reporting new prescriptions for indications commercially available for over one year (GBM, MPM, NSCLC) starting Q1 2026, focusing on active patients and new product launches like Optune Pax.
Analysis
This 8-K provides the full financial picture for 2025 and critical forward-looking guidance for 2026. The projected Adjusted EBITDA of $(20) million to $0 million for 2026 marks a significant step towards profitability, which is a key positive for investors. While revenue growth is expected to slow slightly, the expansion of active patients and the recent FDA approval for Optune Pax (reiterated in the filing) provide new growth avenues. The resignation of the Chief Medical Officer is a notable executive change that warrants attention, but the overall financial trajectory and operational momentum appear to be strengthening. Investors will likely focus on the company's ability to execute on its profitability guidance and the commercial rollout of Optune Pax.
At the time of this filing, NVCR was trading at $14.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $9.82 to $22.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.